Clinical trial
Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab…
NCT00069758 · Cephalon, Industry · Completed
Key facts
| NCT number | NCT00069758 |
|---|---|
| Title | Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma |
| Official title | A Multi-Center Phase II Study to Investigate the Safety and Activity of SDX-105 (Bendamustine) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab |
| Lead sponsor | Cephalon, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | SDX-105 |
| Enrollment | 72 |
| Start date | Sep 1, 2003 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Oct 2, 2003 |
| Last update posted | May 9, 2014 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: